

AMENDMENT N° 2
(hereinafter Amendment)

to the
Clinical Site Agreement (hereinafter Agreement)
dated 25.02.2021 and Amendment No 1 dated

This Amendment is made by and between

Bayer AG

Registered office: Kaiser-Wilhelm-Allee 1, 51373
Leverkusen, Germany and having offices at
Muellerstrasse 178, 13353 Berlin, Germany
VAT No.: DE123659859

Registered with the Commercial Register kept by
Commercial Register B, Cologne, Amtsgericht (Local
Court)

Represented by: Parexel International (IRL) Limited,
One Kilmainham Square, Inchicore Road, Kilmainham,
Dublin 8, Ireland

(hereinafter referred to as the “**Sponsor**”)

and

Fakultná nemocnica Nitra

with its registered seat at: Špitálska 6,
950 01 Nitra

Slovak Republic

ID No.: 17336007

Tax ID No.: 2021205197

VAT No.: SK2021205197

Represented by JUDr. Marian Korytiak, PhD., Director
(hereinafter referred to as the “**Center**”)

and

MUDr. Gabriela Pavlovičová

Address: Malá Kamenná 10
949 01 Nitra

Slovak Republic

Workplace: Fakultná nemocnica Nitra, Clinic of
Ophthalmology, Špitálska 6, 950 01 Nitra, Slovak
Republic

(hereinafter “**Principal Investigator**”)

Protocol No: 20968 (hereinafter Protocol)

“Randomized, Double-Masked, Active-Controlled, Phase 3
Study of the Efficacy and Safety of High Dose Aflibercept in
Patients With Neovascular Age-Related Macular Degeneration”
(hereinafter Study) Aflibercept (hereinafter Study Drug)

DODATOK č. 2
(ďalej ako dodatok)

k
zmluve o klinickom skúšaní (ďalej len „zmluva“)
zo dňa 25.02.2021 a dodatku č. 1 zo dňa

Tento dodatok sa uzatvára medzi

Bayer AG

so sídlom: Kaiser-Wilhelm-Allee 1, 51373 Leverkusen,
Nemecko a s pracoviskom Muellerstrasse 178, 13353
Berlin, Nemecko

DIČ: DE123659859

zapísaná v obchodnom registri vedenom Amtsgericht
(Local Court), Cologne, Commercial Register B

konajúca: Parexel International (IRL) Limited, One
Kilmainham Square, Inchicore Road, Kilmainham, Dublin
8, Irsko

(ďalej len “**Zadávateľ**”)

a

Fakultná nemocnica Nitra

so sídlom: Špitálska 6

950 01 Nitra

Slovenská republika

IČO: 17336007

DIČ: 2021205197

IČ DPH: SK2021205197

Zastúpená JUDr. Marian Korytiak, PhD., riaditeľom
(ďalej len “**Centrum**”)

a

MUDr. Gabriela Pavlovičová

Adresa: Malá Kamenná 10
949 01 Nitra

Slovenská republika

pracovisko: Fakultná nemocnica Nitra, Očná klinika, Špitálska
6, 950 01 Nitra, Slovenská republika

a týka sa

protokolu č.: 20968 (ďalej protokol)

„Randomizované, dvojito maskované, aktívne kontrolované
klinické skúšanie 3. fázy hodnotiace účinnosť a bezpečnosť vysokej
dávky afliberceptu u pacientov neovaskulárnou vekom
podmienenou degeneráciou makuly“ (ďalej len „skúšanie“)
Aflibercept (ďalej len „skúšaný produkt“)

<p>WHEREAS, SPONSOR is the sponsor of the multi-center/multi-centre Study to clinically evaluate the Study Drug;</p> <p>WHEREAS, SPONSOR has contracted with PAREXEL Parexel International (IRL) Limited to act as SPONSOR's representative in managing the Study for SPONSOR, in accordance with the Protocol;</p> <p>WHEREAS, the parties have entered into the above-referred Agreement;</p> <p>WHEREAS the parties agreed to delete and replace in its entirety Exhibit A (Payment Schedule and Budget) – Detailed Budget of the Agreement due to Protocol Amendment Extension Period (Year 3).</p> <p>The budget for Year 3 is split 40% for the Institution and 60% for the study team. The exact budget split, which is included in the Schedule of Payments and Budget annex, is shown in the table below</p>	<p>KEĎŽE ZADÁVATEĽ je zadávateľom multicentrického skúšania skúšaného produktu;</p> <p>KEĎŽE, ZADÁVATEĽ uzavrel zmluvu so spoločnosťou PAREXEL Parexel International (IRL) Limited, aby konala ako zástupca ZADÁVATEĽA pri riadení skúšania pre ZADÁVATEĽA v súlade s protokolom;</p> <p>KEĎŽE zmluvné strany uzavreli vyššie uvedенú zmluvu;</p> <p>KEĎŽE sa zmluvné strany dohodli na vypustení a úplnom nahradení prílohy A (Harmonogram platieb a rozpočet) detailný rozpočet zmluvy z dôvodu Dodatku k protokolu a jeho predĺženia obdobia platnosti (3. rok štúdie);</p> <p>Rozpočet pre rok 3 je delený v pomere 40% pre Inštitúciu a 60% pre štúdiálny tím. Presne delenie rozpočtu, ktorý je súčasťou prílohy Harmonogram platieb a rozpočtu uvádzame v tabulke nižšie</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Visit Description (27)	Slovak Republic	Sub-Study: Year 3
-------------------------------	------------------------	--------------------------

Description	Short Name	Institution	Institution Pharmacy	Institution Local lab	PI	Sub I	Study Nurs
Mandatory Masked Transition Period-Week 96-E01	W96-E01	€ 363.54	€ 16.24		€ 272.66	€ 272.66	€ 72.7
Mandatory Masked Transition Period-Week 100-E02	W100-E02	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
Mandatory Masked Transition Period-Week 104-E03	W104-E03	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
Mandatory Masked Transition Period-Week 108-E04	W108-E04	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
Open-label Part-Week 110	W110	€ 0.00	€ 0.00		€ 0.00	€ 0.00	€ 0.0
Open-label Part-Week 112-E04.1	W112-E04.1	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
Open-label Part-Week 114	W114	€ 0.00	€ 0.00		€ 0.00	€ 0.00	€ 0.0
Open-label Part-Week 116-E04.2	W116-E04.2	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
Open-label Part-Week 118	W118	€ 0.00	€ 0.00		€ 0.00	€ 0.00	€ 0.0
Open-label Part-Week 120	W120	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
Open-label Part-Week 122	W122	€ 0.00	€ 0.00		€ 0.00	€ 0.00	€ 0.0
Open-label Part-Week 124-E5.1	W124-E5.1	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
Open-label Part-Week 126	W126	€ 0.00	€ 0.00		€ 0.00	€ 0.00	€ 0.0
Open-label Part-Week 128-E5.2	W128-E5.2	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
Open-label Part-Week 130	W130	€ 0.00	€ 0.00		€ 0.00	€ 0.00	€ 0.0
Open-label Part-Week 132-E06	W132-E06	€ 478.15	€ 16.24		€ 358.61	€ 358.61	€ 95.6
Open-label Part-Week 134	W134	€ 0.00	€ 0.00		€ 0.00	€ 0.00	€ 0.0
Open-label Part-Week 136-E06.1	W136-E06.1	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
Open-label Part-Week 138	W138	€ 0.00	€ 0.00		€ 0.00	€ 0.00	€ 0.0
Open-label Part-Week 140-E06.2	W140-E06.2	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
Open-label Part-Week 142	W142	€ 0.00	€ 0.00		€ 0.00	€ 0.00	€ 0.0
Open-label Part-Week 144	W144	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
Open-label Part-Week 146	W146	€ 0.00	€ 0.00		€ 0.00	€ 0.00	€ 0.0
Open-label Part-Week 148-E07.1	W148-E07.1	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
Open-label Part-Week 150	W150	€ 0.00	€ 0.00		€ 0.00	€ 0.00	€ 0.0
Open-label Part-Week 152-E07.2	W152-E07.2	€ 339.88	€ 16.24		€ 254.91	€ 254.91	€ 67.9
EOS or ED-Week 156	EOS-W156	€ 312.04	€ 0.00		€ 234.03	€ 234.03	€ 62.4
Total:		€ 5,572.17	€ 243.60		€ 4,179.13	€ 4,179.13	€ 1,114.4

<p>WHEREAS, the parties are jointly willing to amend the above-referred Agreement;</p> <p>Now, therefore the above-referred Agreement shall be amended and the following Amendment No. 2 to the Clinical Trial Agreement shall enter into force on the date of signing by both Parties and shall</p>	<p>KEĎŽE zmluvné strany majú spoločnú vôľu zmeniť a doplniť uvedenú zmluvu;</p> <p>sa teraz preto uvedená zmluva mení a dopĺňa a nasledujúce zmenené a doplnené znenie .</p> <p>Dodatok č. 2 k Zmluve o klinickom skúšaní nadobudne platnosť dňom podpísania oboma zmluvnými stranami a účinnosť dňom zverejnenia dodatku č. 2 v Centrálnom registri zmlúv.</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

become effective on the date of publication of Amendment No. 2 in the Central Register of Contracts.

All other terms and conditions of the above-referred Agreement remain unchanged and in full force and effect.

IN WITNESS WHEREOF, the parties hereto have set their hands in triplicate with the intention that this is a binding agreement to amend as provided herein.

Všetky ostatné podmienky vyššie uvedenej zmluvy zostanú nezmenené a v plnej platnosti a účinnosti.

NA DÔKAZ TOHO strany tejto zmluvy podpísali tri kópie tejto zmluvy so zámerom, že ide o záväznú zmluvu, ktorá bude upravená spôsobom stanoveným v tomto dokumente.

**Zadávateľ prostredníctvom svojho oprávneného zástupcu Parexel International (IRL) Limited / Sponsor
by its authorized representative Parexel International (IRL) Limited**

Miesto / Place Prela

Dátum / Date 26.4.2025

Meno a priezvis
Funk

**Cent
Fakultná**

Miesto / Place _____

Dátum / Date _____

JUDr. Mari

245919 2090

Hlavný skúšajúci / Principal Investigator

Miesto / Place NITRA

Dátum / Date 22.5

Acknowledged and

I, Sub-Investigator

address Benkova 2
Republic, acknowledge and agree by signing of
this document to perform my obligations to the
extent stipulated by the Protocol and Study
Instructions.

Dr. Mariana Ďuríková,
19 11 Nitra, Slovenská
o dokumentu beriem
na vedomie a súhlasím s plnením svojich
povinností v rozsahu stanovenom Protokolom a
pokynmi k Štúdiu.

Práca Lenka Ďuríková
Slovak Republic
19 11 Nitra, Slovenská

MUDr. Mariana Ďuríková

MUDr. Mariana Ďuríková

Potvrdené a odsúhlasené:

Ja, štúdiijná sestra, Eva Hatiarová, adresa: 951 43 Jelšovce 224, Slovenská republika, podpisom tohto dokumentu beriem na vedomie a súhlasím s plnením svojich povinností v rozsahu stanovenom Protokolom a pokynmi k Štúdiu.

Acknowledged and agreed:

I, Study Nurse, Eva Hatiarová, address 951 43 Jelšovce 224, Slovak Republic, acknowledge and agree by signing of this document to perform my obligations to the extent stipulated by the Protocol and Study Instructions.



13.5. 2023

Date / Datum